Search
Leflunomide
go.drugbank.com/drugs/DB01097ApprovedInvestigationalLeflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
Cefoxitin
go.drugbank.com/drugs/DB01331ApprovedInvestigationalIt is derived from cephamycin C, which is produced by <i>Streptomyces lactamdurans</i>.
Fludeoxyglucose (18F)
go.drugbank.com/drugs/DB09502ApprovedInvestigationalIt is administered by intravenous injection.
Human botulinum neurotoxin A/B immune globulin
go.drugbank.com/drugs/DB14115Approved[L39819,L39824] BabyBIG (human-derived botulism immunoglobulin) was approved for use by the FDA in 2003[L39814] and has since been used to treat more than 2100 cases of infant botulism. … [L39834] It is produced and distributed by the Calfornia Department of Public Health's Infant Botulism Treatment and Prevention Program[L39829] and comprises IgG antibodies derived from pooled adult plasma
BNT162a1 SARS-CoV-2 Vaccine
go.drugbank.com/drugs/DB15697Experimental[L15002, L15007] BNT162a1 is a uridine mRNA (uRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.
BNT162c2 SARS-CoV-2 Vaccine
go.drugbank.com/drugs/DB15698Experimental[L15002, L15007] BNT162c2 is a self-amplifying mRNA (saRNA) vaccine formulated in lipid nanoparticles for delivery via intramuscular injection.
Daridorexant
go.drugbank.com/drugs/DB15031ApprovedInvestigational[A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023. … Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning.
Isocarboxazid
go.drugbank.com/drugs/DB01247Approved[T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.
Anthrax vaccine
go.drugbank.com/drugs/DB11003ApprovedInvestigational[L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.
Maraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the